ArticleAnnals of surgical oncology2024
Impact of Metastatic Lymph Nodes on Survival of Patients with pN1-Category Esophageal Squamous Cell Carcinoma: A Long-Term Survival Analysis.
Article in Annals of surgical oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 16 citations in OpenAlex.
- Identification of STAT1 as a biomarker for lymph node metastasis in esophageal squamous cell carcinoma.Journal of molecular histology · 2026Article
- The Ideal Number of Examined Lymph Node Stations for Accurate Nodal Staging and Prognosis in Pathological T1-2 Esophageal Squamous Cell Carcinoma: A Large-Scale Multicenter Cohort Study.Annals of surgical oncology · 2026Article
- Thoracic duct ligation during esophagectomy fails to prevent chylothorax or improve survival: a propensity score matched cohort study.Esophagus : official journal of the Japan Esophageal Society · 2026Article
- CT-based Extranodal Extension for Nodal Staging and Prognostic Stratification in Surgically Resectable Esophageal Squamous Cell Carcinoma.Radiology. Imaging cancer · 2026Observational
- Development and validation of a nomogram for predicting long-term survival in pN + esophageal squamous cell carcinoma treated using radical resection without neoadjuvant therapy.Annals of medicine · 2025Article
- Article
- Long-term survival outcomes of esophageal squamous cell carcinoma with intraoperative thoracic duct ligation: a large-scale propensity score matching analysis.Frontiers in oncology · 2025Article
- Evolution of lymph node staging in esophageal squamous cell carcinoma: insights from lymph node metastatic stations.Frontiers in oncology · 2025Review
- Survival outcomes of intrathoracic vs. cervical anastomosis post-esophagectomy in middle and lower thoracic esophageal squamous cell carcinoma: a retrospective propensity score matching analysis.Frontiers in oncology · 2025Article
- Number of Resected Lymph Nodes and Survival Status in Node-Negative Esophageal Squamous Cell Carcinoma: A Cohort Study.International journal of general medicine · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundThe morbidity and mortality rates of esophageal squamous cell carcinoma (ESCC) are high in China. The overall survival (OS) of patients with ESCC is related to lymph node (LN) metastasis (LNM). This study aimed to discuss the impact of metastasis in LN stations on the OS of patients with pathologic N1 (pN1) ESCC.
methodsData were obtained from the Esophageal Cancer Case Management database of Sichuan Cancer Hospital and Institute (SCCH-ECCM). Additionally, data of patients with pN1-category ESCC collected between January 2010 and December 2017 were retrospectively analyzed.
resultsData from 807 patients were analyzed. The median OS of the patients with one metastatic LN (group 1) was 49.8 months (95 % confidence interval [CI], 30.8-68.9 months), whereas the OS of those with two metastatic LNs (group 2) was only 33.3 months (P = 0.0001). Moreover, group 1 did not show a significantly longer OS than group 2.1 (patients with 2 metastatic LNs in 1 LNM station; P = 0.5736), but did show a significantly longer OS than group 2.2 (patients with 2 metastatic LNs in 2 LNM stations; P < 0.0001). After propensity score-matching, the 5-year survival rate for group 1 was 28 %, whereas that for group 2 was 14 % (P = 0.0027).
conclusionsThe OS for the patients with one metastatic LN in one LNM was not significantly longer than for the patients with two metastatic LNs in one LNM station. Patients with one LNM station had a significantly longer OS than those with two LNM stations. Thus, the number of LNM stations is a significant determinant of OS in pN1 ESCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.